Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer

NCT01934335 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

12

Enrollment

OTHER

Sponsor class

Stopped Drugs unavailable

Conditions

Invasive Breast Cancer

Interventions

DRUG: Vandetanib
OTHER: Placebo

Sponsor

Ronald Weigel

Collaborators

[object Object]